Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866904 · ClinicalTrials.gov registry record
Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 9,284
- Enrollment target
NCT01866904: Clinical Trial study, sponsored by AstraZeneca.
NCT01866904 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 9,284 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01866904 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 9,284 participants
- Enrollment target
Study Summary
THis study is intended to provide contemporary data on the burden of disease in patients 1 to 3 years post-MI, including a description of patient characteristics, current treatment patterns, rate of major CV events, and healthcare resource utilization in a 'real world' patient population at high atherothrombotic risk.
Primary Outcome
Event rates (time to first occurrence of any event from the composite of MI, unstable angina with urgent revascularization, stroke or death for any cause) in a three-year follow-up period.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,284 participants |
| Start Date | 2013-06-19 |
| Est. Completion | 2017-03-31 |
Why NCT01866904 stopped before completion
NCT01866904 is an observational study that tracks outcomes without assigning an intervention. Its 9,284 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01866904 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01866904 about?
NCT01866904 is a clinical study titled "Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients". THis study is intended to provide contemporary data on the burden of disease in patients 1 to 3 years post-MI, including a description of patient characteristics, current treatment patterns, rate of major CV events, and healthcare resource utilization in a 'real world' patient population at high ath...
What is the current status of trial NCT01866904?
This trial is currently terminated. The enrollment target is 9,284 participants. The study started on 2013-06-19. Estimated completion is 2017-03-31.
Who is sponsoring clinical trial NCT01866904?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT06284408 · 9,460 participants · NA
Centralized Screening Unit (CSU) at Montefiore-Einstein
- NCT05080673 · 9,500 participants · NA
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI